Seeking Alpha

Steve Rosenman's  Instablog

Steve Rosenman
Send Message
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of... More
  • It's All About Anchor  52 comments
    Jul 9, 2013 9:41 AM | about stocks: AMRN

    Today's releases were a net neutral for me. I liked the script update and we will exceed analyst consensus estimates.

    The financing amount and timing seem strange. It's not a lot of money -- not nearly enough for self Anchor launch (a good thing) and the only guess I have on 'why now' is to be prepared in worse case scenario should a favorable BO or partnership not materialize - also to get the news out way in advance of Anchor to maintain focus on Anchor during Q3-Q4. A setup like this seems to favor a partner deal, as AMRN would require money to maintain Marine sales and Reduce It development. Just speculation though...

    I don't like the equity deal, vs non-dilutive financing, seems to suggest creditors believe AMRN more risky now.

    Maintain my $28-32 target and BO.

    Stocks: AMRN
Back To Steve Rosenman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (52)
Track new comments
  • It's all about the FDA, and ANCHOR/NCE are presently victims of their whims.
    9 Jul 2013, 02:43 PM Reply Like
  • Deja Vu. This smells like the setup / fix is in. First the NCE non decision. Secondly the meta analysis fish oil study. Thirdly, Summer Street opining that the ANCHOR indication won't be approved and misquoting a doctor and attributing the quotes to an "insider". The latest is the prostate cancer business picked up and spread on the newswire.


    The timing and frequency of discrediting articles and remarks are not by chance. If this isn't an all out effort to kill Vascepa/Amarin, I don't know what is.


    This is suspiciously like Arena where the "rat tumor" problems killed the stock. Both Arena and the FDA were aware of the rat tumor business well prior to the Adcom. It is my understanding that Arena was told by the FDA that the rat tumor situation was not a problem only to mysteriously turn up in the briefing documents and become a true controversy during the Adcom. There was a real effort to destroy Arena and it almost worked. I can almost guarantee you that history will repeat. When the briefing documents come out there will be 2 items being discussed. 1. Questionable efficacy in mitigating coronary events (despite the JELIS trial) . Afterall that is why the FDA asked for the REDUCE-IT study. 2. Questions as to why Vascepa should be indicated for a much larger population because of the questions surrounding prostate cancer.


    Right or wrong doesn't matter here. Create enough fear doubt and uncertainty and it might effect panel member votes.
    11 Jul 2013, 03:25 PM Reply Like
  • We have a nice study run by the National Cancer Institute, NIH-AARP study, published this year, 2013, and it never gets any mention anywhere.


    "Eicosapentanoic acid (EPA) intake was related to decreased risk of fatal prostate cancer (HRQ5 vs. Q1, 0.82; 95% CI, 0.64-1.04; Ptrend = 0.02)."


    National Cancer Institute.


    Instead, we get a crackpot Brasky study that is below standards that is touted everywhere. Brasky even found that there was no link between fish oil and prostate cancer in another study of his that was published!




    Big time organization to try to trash Fish Oil in the public's eye.
    11 Jul 2013, 04:31 PM Reply Like
  • And since the 2008 Harvard Study (Ivy League), here:


    found that


    During 382 144 person-years of follow-up, 2161 men were diagnosed with prostate cancer and 230 died of prostate cancer. Fish intake was unrelated to prostate cancer incidence. Survival analysis among the men diagnosed with prostate cancer revealed that those consuming fish ≥5 times/wk had a 48% lower risk of prostate cancer death than did men consuming fish less than once weekly [relative risk (RR) = 0.52; 95% CI: 0.30, 0.91; P for trend = 0.05]. A similar association was found between seafood n−3 fatty acid intake and prostate cancer mortality (RRQ5 versus Q1 = 0.64; 95% CI: 0.42, 0.99; P for trend = 0.02). These associations became stronger when the analyses were restricted to clinically detected cases


    So, knowing the benefits of Fish/Fish Oil in helping prevent prostate cancer mortality, don't you think PEOPLE WITH PROSTATE CANCER ARE TAKING FISH OIL!? Could that be the reason they are seeing the correlation?
    11 Jul 2013, 04:35 PM Reply Like
  • I'm with ya brother.....but the effort here to hurt Amarin is palpable. I wonder if the current environment had anything to do with Amarin's decision to do an early secondary. The timing is simply too suspect.
    11 Jul 2013, 04:51 PM Reply Like
  • To avoid dilution by entering into a debt agreement that is expensive (if taken to term) and requires pledging all your assets as collateral....just to turn around and dilute near the 52 week low (when there is no immediate need for cash) doesn't make sense.


    Something is afoot and as usual we will be the last to know. Makes me wonder if the institutional dumping at the end of Q2 was a warning of sorts or simply impatience. Again, I pray for some clarity during the Aug CC. If I see the usual ambiguity as respects what direction we take on the ANCHOR marketing strategy and management fails to justify diluting at this absurd price, I'm gone.


    Amarin needs to pick a path and stick to it. This keystone cops routine is costing the company many millions and costing shareholders equally.
    9 Jul 2013, 03:27 PM Reply Like
  • I have to admit the stock offering at this time is a head scratcher. But one thing sticks out like a sore thumb.
    I have always found it curious the next earnings date was announced right after the previous one. It is very unusual to put out such a date three months in advance. Normally, a company announces a few weeks before making the earnings available. And yet, AMRN announced an August 7 date very very early.
    We have a shareholders meeting on July 9. The day before the shareholder meeting, a thirty day stock offering is announced. That occurs on July 8. Now count forward thirty days. What date is thirty days from July 8 ? August 7, the exact date of the next announced earnings report. A date that was set two months ago.
    It just leads me to believe AMRN did not wake up two weeks ago and decide to dilute. It almost looks like certain dates were chosen for a reason. I could make a guess or two as to why, but I will hold off.
    I think a plan is in place , and has been for awhile. I agree with people that say the management could be a little more forth coming. It would not hurt them to be a little less secretive. I guess this is a time you have to believe in what the company is doing.
    I have just found it to be mildly curious that a early earnings date announcement happens to fall on the exact date a stock dilution wraps up. Take that coincidence for what it may be worth.
    9 Jul 2013, 04:12 PM Reply Like
  • You've got an interesting point - please step over the line and give a scenario or two on what you think the July 8 / August 7 link COULD be. Both the timing and amount looked significant to me. No penalty for being wrong, btw.


    9 Jul 2013, 05:25 PM Reply Like
  • Look at the timeline. Jefferies meets with AMRN April 9 & 10. The latest conference call was May 9. The two questions asked by Jefferies were softball questions about plans to commercialize ANCHOR. Reading the answers now you can tell JZ tap danced the answers, and self corrects himself. He almost went off script.
    At that time, JZ HAD to know financing was coming. AMRN only stated they had enough money to go another year. No one ever asked if dilution was in the cards, people just assumed it wasn't based on the statement that enough money was available.
    Now we get to the vote to grant more financing at this morning's meeting. When the next conference call date was announced, I think the dilution had already been planned. They planned on a yes vote for more financing. The conference call date was set, along with the shareholder's meeting date of July 9. Thirty day financing tied to the conference call date and shareholder meeting date.
    Now, what could this mean ? I am guessing that a partnership is already in the works. I think AMRN does not really want this, but will go this route. The two underwriters of the dilution must feel fairly comfortable in the future of AMRN to underwrite this offering. You can also note that the PARTNER link is still up on the AMRN website.
    Another hint to me is that certain people are now saying a run up to ANCHOR will start in August. That is slightly early for a bio run up of a December decision, even with an October AD COM date. But a run up would be in the cards if a partnership is revealed in August.
    Just a feeling, but I smell hedge funds waiting to get in cheap, and then turning this bus around to make some serious cash. I am almost sure this financing was not an air tight secret in the financial world. Hedge funds knew enough to dump and short until this moment. Now they can jump on board, and make the same money again on the way up. Such is the way of Wall Street, the most rigged casino in the world.
    So, short answer to your question, I think a partnership is in the works already. Who, and how ? Unknown. I come to this conclusion trying to put together puzzle pieces.
    Again, I say it would be helpful if the company would be a little more forthcoming to the shareholders. It would go a long ways towards soothing the anger that shareholders now feel towards management. As a shareholder, I know a dilution, with a very vague explanation, is not near what I want to hear. More clarity would be very helpful.
    10 Jul 2013, 02:47 AM Reply Like
  • P.S. What better way to pay back the hedge funds that got hosed in December thinking a buy out was coming then by letting them buy shares in July on the cheap ? How much more would it cost to buy all those shares in thirty days on the open market ? I am guessing more than $ 5.75 a share.
    10 Jul 2013, 02:58 AM Reply Like
  • If they were bought today the acquirer would then have 25million shares at a 5.75 discount. Because the cash for that 25m would be the acquirers and it was done at 5.75ish. I hope that makes sense and I hope I have explained it well enough that you understand. This does not prevent any deals being done imminently.
    9 Jul 2013, 05:16 PM Reply Like
  • Obviously he was wrong in his past predictions. He doesn't sound too happy about the equity financing (rightfully so). I think we all need to be worried. I think there's really no interest from Big Pharma. Not sure what to do - just confused as hell,
    9 Jul 2013, 05:30 PM Reply Like
  • I am with SR on not being happy that they have resorted to raising equity at this point. Why not do it that way last year...things can't be progressing fast enough on partnership behind the scenes and/or the cash burn may not be slowing fast enough.


    Another less likely scenario is that it may be a way of some existing tutes who hold /have held AMRN being able to buy in at a good price in larger bundles whilst at the same time effectively trying to signal to the market where they see the floor price.


    I remain long AMRN to the tune of some 4,500 shares acquired last year. This story has taken longer than hoped to play out, but at these prices I am in two minds whether to buy more to average down vs thinking AMRN has more fundamental issues and it would be good money after bad. Jury remains question the product itself is good.
    9 Jul 2013, 05:32 PM Reply Like
  • Steve,
    Again and again incompetent management destroying a blockbuster drug potential. They say one thing and does another. Very odd timing for this dilution.
    9 Jul 2013, 05:32 PM Reply Like
  • Make no mistake, had this dilution occurred back in November instead of today, AMRN would not have had a need to deal with the mafia for a loan nor would they have had to dilute today.


    Additionally, had management decided to partner the drug back in November and perform some sort of dilution instead of creating the current environment of doubt, AMRN would probably be back in the teens instead of approaching the $4's.


    AMRN has lost all credibility and it is becoming apparent that this management team has not the slightest clue when it comes to financial planning for the company. This late arriving dilution reeks of mismanagement and poor financial execution.


    Steve, you can maintain your expected price target all you want but it is absolutely meaningless at this point in time. With this management team, $28-30 is a pipe dream.


    You are absolutely correct when you state that creditors consider AMRN to be risky. It didn't have to be this way, but unfortunately it has come down to this.


    Shareholders will be lucky to see low teens ever again and this assumes a BO.
    9 Jul 2013, 05:33 PM Reply Like
  • Author’s reply » Source close to Omthera says AZN still eyeing Amarin.
    9 Jul 2013, 05:33 PM Reply Like
  • Steve, no disrespect intended, but please stop quoting your "sources" and please stop with the $28-32 BO. The info your "sources" have given you has yet to pan out. We've heard AZN, GSK, PFE, etc., etc. Maybe it's true but me thinks these companies will wait until AMRN is on its knees gasping it's final breath before they act. Either that or they will just purchase the patents from the mafia loan sharks when AMRN defaults.


    You do a good job discussing the drug and the market it serves. If you do this, you will go a long way in helping people see the potential. But please leave your prognostications out of your analysis.


    Re:what management is doing, it is simple: they are going for their 3rd 1-10 reverse split in a decade.
    9 Jul 2013, 05:44 PM Reply Like
  • Steve - Unless you can verify the story, sources and facts, I wouldn't print stuff like this.......not even in a blog. Your credibility is important. Don't screw that up.
    9 Jul 2013, 06:13 PM Reply Like
  • Author’s reply » This source is one of the guys that started OMTH and brought Epanova through the clinical trials. He is no longer with the company. He has consulted with AZN and one of the major fish oil supply companies within the past 6 months. His commentary suggests that AZN has a broader plan regarding Omega-3 class drugs, or at very least expansion of their cardio program.
    9 Jul 2013, 10:04 PM Reply Like
  • Thank you for that information. We'll see what happens. Sounds like a sound "source". AZN didn't pay much for Omthera so its not like their out of ammo.
    10 Jul 2013, 01:37 AM Reply Like
  • Author’s reply » Just like I've stopped guessing at NCE timing, Im going to stop guessing about what he heck mgt is up to...just sticking with fundamentals of drug and the market it serves.
    9 Jul 2013, 05:33 PM Reply Like
  • the crazy eyed suspicious one in me thinks the unprotested walk down was some sort of a message from someone with enough stones , perhaps even short shares, to make it known "let us back in on the cheap before The Big Bang and we will introduce stability afterward." Current large holders sort of understand per "you don't lose til you sell". Short Int dropped yet another 1.4M in two weeks, Q'trly scrips are up 4.4X and even Furinestain is getting the "cover" message out. The main ones tossed to the WSWolves were skittish/fast money retail and some renegade funds. Shades of Jan 2011. Otherwise true, the timing and the amount seem daft. If I turn out to be right per the bi-weekly SI and quarterly 13 reports, and of course Anchor ADCOM, lets all meet back here for a Ya Heard It Here First drum circle. If the blackout tint Suburbans start blocking my driveway, I might miss the lecture but you will know ...


    adding reply to other comments, though its easy to think a $250 or 300M raise right after MARINE approval would have been less painful, there is some doubt things would be different now, except for 20 million shares of newly pissed off Tutes. I do not praise this this move but assuming alternative scenarios would be fine is simplistic. This is still an ANCHOR Co and assuming that pays off, giving up another 10% may be the price we pay
    9 Jul 2013, 06:42 PM Reply Like
  • AMRN management is preparing for ANCHOR delay which they know is coming. They realize that a BO or partnership will not occur without ANCHOR. They decided to dilute months ago, hence the steady decline in stock price. This is exactly why institutions haven't jumped back in. AMRN management has made several critical miscalculations and shareholders are paying for it dearly. The CEO pumped a buyout... no buyout (Saying AZN is still interested is laughable). GIA is the last option... hired a sales force... Said the next 60-90 days will be exciting... not so...The CEO said they have enough cash to get them to 2014... dilute.
    9 Jul 2013, 10:06 PM Reply Like
  • still long AMRN
    but what I don't get is why would anyone buyout AMRN in double digits, when management is selling sub 6 ?
    9 Jul 2013, 10:44 PM Reply Like
  • I'd say it all depends on the status of ANCHOR marketing, as of today, they don't have it, if they get it, that adds value to the PPS.
    9 Jul 2013, 10:46 PM Reply Like
  • What is happening here is that "shorties" are fearful because they know what is coming and "longs" are tired, frustrated and angry. That's all. I see and understand both sides.


    Do you remember dillution by January 2011?
    The price was very close the 7s. Everybody was also very angry with management because the dillution by then.
    Nobody thought, NOBODY, that the price would hit $19 just six months after.
    And that were because phase III results with all endpoints met and side effects like placebo. Now we are talking about NDA, we are talking about getting into the market, in the $40 Billion market. And that is the reason , the money, the potential money. The market will reward Amarin's shareholders.
    10 Jul 2013, 05:20 AM Reply Like
  • Dilution is the insurance policy board wanted to protect itself if partnership and or BO does not happen as planned. As per j Bruno company has no plans to hire in mass so I believe something already in works. They believe anchor and ad com will go fine. Stay the course. Patience will prevail
    10 Jul 2013, 07:06 AM Reply Like
  • By the way OMTH was BO 3 weeks after their offering. So don't tell me nothing can be in works
    10 Jul 2013, 07:07 AM Reply Like
  • Author’s reply » Good observation coop
    10 Jul 2013, 10:26 AM Reply Like
  • steve,


    how can you maintain a $28-$30 BO price when they increased the shares by 20M. that would mean your previous target would have to be $32-$35.
    10 Jul 2013, 11:58 AM Reply Like
  • He's pulling the number out of his ass. Just know that if they were to sell it would probably be higher than 6 and atleast 15 I'm guess. More would be great, but definitely not 28-32--lets get real
    10 Jul 2013, 02:33 PM Reply Like
  • Author’s reply » yazz - if out at $7, you might as well sell just don't get it.
    10 Jul 2013, 04:35 PM Reply Like
  • Author’s reply » bhorgan, a good observation. I suppose should the financing occur, my target would be more in line $24.50-$26.50, considering dilution.


    That said, I believe there could be some upside when AMRN is able to operate from a position of strength (Anchor approval/NCE/continue script growth), so $28-30 still entirely possible and likely with BO scenario.
    10 Jul 2013, 04:36 PM Reply Like
  • Author’s reply » You should get real, Anchor is 2/3 of American population. If you believe they would sell the company for less than $25, you don't understand what is going on.
    10 Jul 2013, 04:43 PM Reply Like
  • Steve, Anchor may be 2/3rd of American population but it first needs to be approved and then it needs docs to prescribe it. How on earth are docs going to know about Vascepa with the miniature sales force AMRN maintains? At some point, the sales reps are going to get burned out. I think we are already seeing it with the diminishing growth rates in Marine sales.


    ARMN has had well over a year to put together a partnership but have failed to do so. Now management is talking about launching Anchor on their own.


    The stock now sits at $5.35 and shorts are still firmly in control. How can you still write that people do not know what is going on if they cannot understand why the company will not be sold for under $25?


    I think what people can't understand is how AMRN management has brought this company back to 2 1/2 year lows. WS has absolutely no faith in what management says or does. Most likely, AMRN falls into the $4's by tomorrow or early next week.


    If AMRN management gave a damn at all about the share price, they would've inked a partnership deal and begun to sell the heck out of V. Now we can expect AZN to begin taking market share in roughly 10 months.


    The silent approach management has taken is absolutely unbelievable.
    11 Jul 2013, 06:27 PM Reply Like
  • According to page 6 of the June, 2013 Amarin investor presentation, the US adult population is 223.8M. ANCHOR represents 36M of the US adult population or 16%. ANCHOR is not 2/3 or 67% of the US adult population.

    11 Jul 2013, 10:07 PM Reply Like
  • HipFree, good catch. I did not bother to argue Steve's %'s. Nonetheless, no matter what the percent, AMRN needs sales help and I do not see any calvary in sight.
    11 Jul 2013, 11:34 PM Reply Like
  • Author’s reply » not a good catch actually. that is what Amarin is saying about diagnosed patients. Check out the LP Institute and WHO, the actual number of people at risk is 2/3.
    12 Jul 2013, 09:23 AM Reply Like
  • Fair enough! Thank you for clarification.
    12 Jul 2013, 11:24 AM Reply Like
  • Steve, please review page 6 of Amarin’s June 2013 investor presentation more closely. The data is based on ”US Adult Population Based on TG levels” and sourced from Datamonitor and Archives of Internal Medicine, 2009;169(6):572-578.


    You stated that “ANCHOR is 2/3 of American population.” As of 2012, according to the United Stated Census Bureau estimate, the American population is 313.9M. Based on your claim, more than 210M (2/3 or 67% of 313.9M) Americans would be in the ANCHOR category.


    I assume that you meant “2/3 of [adult] American population.” If this is the case, then 2/3 or 67% of 223.8M (reference previously cited “U.S. Adult Population Based on TG levels” data) is almost 150M American adults. As clearly documented on page 6 of Amarin’s June 2013 investor presentation, the US adult ANCHOR population is 36M—not210M or 150M.


    If it was more accurate and/or more advantageous for Amarin to cite LP Institute and WHO data, why did Amarin not reference this data? If you are citing LP Institute and WHO data for US adult population, please provide specific figures and references.
    Link to June 2013 Amarin Investor Presentation:

    12 Jul 2013, 04:56 PM Reply Like
  • Author’s reply » they cannot cite that because AMRN is talking about patients, I am talking about potential patients. You can also factor in obesity in U.S. and get to that number, as obesity and high trig in Anchor range are directly related. What are we talking about here...either way, a multi-billion market >$10B potential
    13 Jul 2013, 03:42 AM Reply Like
  • steve, any comments or thoughts on the 8k and details provided by company? thanks as always
    10 Jul 2013, 05:46 PM Reply Like
  • NBC news
    "Fish oils may raise prostate cancer risks, study confirms"


    DHA has double the risk of high-grade prostate cancer.
    Those with the highest blood levels had a 71 percent higher risk of high-grade prostate cancer, compared to those with the lowest levels. Overall, their risk of any kind of prostate cancer was 44 percent higher.



    Vascepa HAS NOT DHA. :)
    10 Jul 2013, 08:41 PM Reply Like
  • Steve,
    Is it possible that Epanova has problems with NDA approval because recent studies say DHA has double the risk of high-grade prostate cancer?


    And what about Lovaza?
    Is it possible FDA wants to change its label?
    11 Jul 2013, 07:37 AM Reply Like
  • Author’s reply » No, not at all.




    WASHINGTON, D.C., July 11, 2013—In response to a new study, “Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial,” published yesterday online in the Journal of the National Cancer Institute, the Council for Responsible Nutrition (CRN), the leading trade association representing the dietary supplement industry, today issued the following statement:
    Statement by Duffy MacKay, N.D., vice president, scientific and regulatory affairs, CRN:


    “The numerous benefits of omega-3 fatty acids from foods (like salmon and sardines) and dietary supplements are well-established for men and women in all stages of life—and this new study does not change those recommendations about the importance of this nutrient. Hundreds of studies over the past two decades have shown omega-3 fatty acids to have positive effects associated with cardiovascular health, perinatal health, inflammation, cognitive function, or cancer. Collectively, this body of research serves as the basis for numerous recommendations from respected organizations, scientific boards and healthcare practitioners that Americans get omega-3 fatty acids in their diets.
    While we encourage researchers to continue to study omega-3 fatty acids with an open mind, it is counterproductive when studying nutrition for researchers to promote their study as if it were the only piece of research that counts. In this case in particular, it is especially disingenuous for the researchers to make the kinds of assertions we’ve seen in the press, given their results are in stark contrast to previous epidemiologic studies1 that not only demonstrate no correlation between omega-3 consumption through fish and/or supplementation and the risk of prostate cancer, but in many cases also showed a protective effect against prostate cancer.
    Further, the researchers were quick to blame dietary supplements even though there is no evidence that anybody in this study took fish oil dietary supplements. In fact, the study demonstrates no cause and effect; it can only purport to show an association between higher plasma levels of omega-3 fatty acids and those whom the researchers advise had an increased rate of prostate cancer.
    One should also consider whether this study could have simply been measuring a biomarker reflecting recent intake of fish or fish oil supplements in a group of high risk cancer patients that had been told to increase their EPA and DHA levels, as compared to a group of non-cancer patients that had not been told to consume more EPA and DHA. Plasma levels of EPA and DHA reflect very recent intake and are considered a poor biomarker of long term omega-3 intake especially when compared to red blood cell levels, which reflect medium term intake. A single fish oil dose (or hearty serving of fish at lunch) results in >100 percent increase in plasma omega-3 levels. So looking at plasma levels in healthy and sick people may only provide insight into the recent habits of these individuals.
    Additionally, the study’s conclusions are also limited by the fact that the study was not designed to evaluate the question the researchers sought to confirm.
    The American Heart Association, the World Health Organization (WHO), the U.S. Institute of Medicine’s Food Nutrition Board (IOM FNB) and the 2010 Dietary Guidelines all have current policies advising Americans to eat more fatty fish to get the benefits of omega-3 fish oils. It is highly unlikely this one study will change that advice. Omega-3s can also be obtained by taking one of the many supplement products on the market. For those consumers who have concerns about prostate cancer or other questions about omega-3 fatty acids, we recommend speaking with your doctor or other healthcare practitioner.”
    12 Jul 2013, 09:24 AM Reply Like
  • Not to mention that if serum Omega 3 levels were causal in prostate cancer, Japanese men would be falling left and right. Yet, the rate of prostate cancer in Japan is 10 times lower than in the US. The "if it bleeds it leads press" had a field day with this one. Slowly but surely it is being discredited and will be forgotten and relegated to the junk science heap. However, PhDs everywhere are thinking up the next bit of garbage to get published and secure their tenure and bring money into their university. Whats next?.................... stay tuned. News at 5pm
    12 Jul 2013, 11:24 AM Reply Like
  • That study is the same thing as saying Calcium causes cancer. If the patients had a higher levels of calcium in their blood would you say Calcium causes cancer. It is a seriously flawed assumption.
    11 Jul 2013, 10:05 PM Reply Like
  • all i can say is amarin will sky rocket in sept, bc if it doesnt im gonna burn down the headquarters lol
    11 Jul 2013, 10:07 PM Reply Like
  • Koko, I hope for you nothing burns at AMRN because, innocent or not, in today's age you will have the fed's knocking on your door for just simply making the statement.
    11 Jul 2013, 11:36 PM Reply Like
  • With my luck your prob right. Jz is probably gonna set me up so amarin can do an insurance job
    12 Jul 2013, 10:10 AM Reply Like
  • This Prostate Cancer Scare is the best opportunity this Co. has had. All eyes are on this Fish Oil scare. If Bruno or Joe or whoever asked for an interview to speak on this it would be granted. You know why? Because people would watch it. It's already out there. It's on the Yahoo Homepage. Hot button this morning. You want to know why this matters? Viewership. Advertisers on these shows want bodies to sell to. This story will work for them. It will also work for Vascepa. At the end of today, THIS day, millions of people can know about this compound. It can be separated from the fear AND be in everyone's eyes. It needs to be! It's not DHA! It's not anywhere near enough that a person who knows the brand name can look up the FAQ on this TOTALLY obscure website. The world is waiting boys. Someone in Bedminster New Jersey better engage! Timing is everything.
    12 Jul 2013, 08:32 AM Reply Like
  • They wont say crap. In case you didnt notice management kinda sucks
    12 Jul 2013, 10:20 AM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.